Barclays PLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Barclays PLC trimmed its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 66.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,546 shares of the biopharmaceutical company's stock after selling 157,367 shares during the period. Barclays PLC owned about 0.09% of Ultragenyx Pharmaceutical worth $4,419,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. nVerses Capital LLC bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $33,000. UMB Bank n.a. raised its stake in Ultragenyx Pharmaceutical by 58.1% during the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 352 shares during the last quarter. True Wealth Design LLC acquired a new position in Ultragenyx Pharmaceutical in the third quarter valued at $43,000. Values First Advisors Inc. bought a new stake in Ultragenyx Pharmaceutical during the third quarter valued at $56,000. Finally, Nomura Asset Management Co. Ltd. acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth about $93,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Trading Up 1.7 %

NASDAQ RARE traded up $0.75 during trading hours on Friday, hitting $44.22. The company's stock had a trading volume of 1,707,822 shares, compared to its average volume of 782,100. The company has a market capitalization of $4.08 billion, a PE ratio of -6.83 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The company's 50-day simple moving average is $49.53 and its two-hundred day simple moving average is $49.36.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating analysts' consensus estimates of ($1.45) by $0.05. The company had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company's revenue for the quarter was up 42.3% on a year-over-year basis. During the same quarter last year, the company earned ($2.23) earnings per share. Research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on RARE. Cantor Fitzgerald restated an "overweight" rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Wells Fargo & Company increased their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a report on Friday. Canaccord Genuity Group reiterated a "buy" rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. TD Cowen boosted their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $88.46.

Insiders Place Their Bets

In related news, CEO Emil D. Kakkis sold 8,273 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total transaction of $413,650.00. Following the sale, the chief executive officer now directly owns 2,195,712 shares in the company, valued at approximately $109,785,600. This trade represents a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Howard Horn sold 7,465 shares of the company's stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now owns 92,301 shares of the company's stock, valued at $4,869,800.76. This trade represents a 7.48 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.